Page last updated: 2024-08-18

pyrroles and Liposarcoma

pyrroles has been researched along with Liposarcoma in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (66.67)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Abdul Razak, AR; Bauer, S; Blay, JY; Clementi, G; Cubedo, R; Fabre, C; Ferretti, S; Guerreiro, N; Halilovic, E; Hütter-Krönke, ML; Italiano, A; Jullion, A; Lin, CC; Orlando, EJ; Quek, R; Sand Dejmek, J; Suarez, C	1
Ardizzoni, A; Bella, MA; Porzio, R; Rossi, G	1
Agresta, S; Antonia, S; Calitri, CE; Chiappori, A; D'Amato, G; Dean, M; Garrett, C; Han, G; Mahmood, ST; Schell, MJ; Vigil, CE; Zhao, X	1

Trials

2 trial(s) available for pyrroles and Liposarcoma

Article	Year
Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib Study. Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, 03-15, Volume: 28, Issue:6 Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Cyclin-Dependent Kinase 4; Humans; Imidazoles; Liposarcoma; Proto-Oncogene Proteins c-mdm2; Purines; Pyrimidines; Pyrroles	2022
Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma. International journal of cancer, 2011, Oct-15, Volume: 129, Issue:8 Topics: Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Histiocytoma, Malignant Fibrous; Humans; Indoles; Leiomyosarcoma; Liposarcoma; Male; Neoplasm Metastasis; Protein Kinase Inhibitors; Pyrroles; Recurrence; Retreatment; Sarcoma; Sunitinib; Survival Rate	2011

Article

Year

Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib Study.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, 03-15, Volume: 28, Issue:6

Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Cyclin-Dependent Kinase 4; Humans; Imidazoles; Liposarcoma; Proto-Oncogene Proteins c-mdm2; Purines; Pyrimidines; Pyrroles

2022

Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma.

International journal of cancer, 2011, Oct-15, Volume: 129, Issue:8

Topics: Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Histiocytoma, Malignant Fibrous; Humans; Indoles; Leiomyosarcoma; Liposarcoma; Male; Neoplasm Metastasis; Protein Kinase Inhibitors; Pyrroles; Recurrence; Retreatment; Sarcoma; Sunitinib; Survival Rate

2011

Other Studies

1 other study(ies) available for pyrroles and Liposarcoma

Article	Year
Long-lasting clinical benefit of sunitinib malate in the treatment of a case of heavily pre-treated metastatic liposarcoma. Anticancer research, 2013, Volume: 33, Issue:3 Topics: Aged; Antineoplastic Agents; Humans; Indoles; Liposarcoma; Lung Neoplasms; Male; Mutation; Neck; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrroles; Receptors, Platelet-Derived Growth Factor; Sunitinib	2013